Private Bid For KCI Signals Growth In Wound Care
Historically, wound care has been a nice tuck-in business for both large medical device and pharmaceutical companies. But that dynamic appears to be changing as advanced technologies are developed that make this sector more attractive as a growth business, evidenced by the large number of recent deals and consolidation going on in this market. The latest example of this trend is the proposed $6.3 billion deal to make publicly traded Kinetic Concepts a privately held company.
You may also be interested in...
Contrary to conventional wisdom, a gradual product rollout, as opposed to a full-court press, may be the best way for device companies to generate maximum value from innovative products.
Indicated for many types of acute and chronic wounds, negative pressure wound therapy kicks off many mechanisms useful in wound healing. However, the devices aren't used in all patients for whom they're indicated for reasons that have to do with inconvenience, logistics and quality of life. Spiracur offers the same negative pressure therapy in a small, entirely mechanical, tether-free disposable device that replaces the cumbersome electric pumps that dominate the market today.
The treatment of chronic wounds is challenging, not only because of the underlying biology, but also because of more practical considerations: fragmentation in the care settings, the logistics of delivering products to patients, and the costs of chronic care. Next generation advanced wound care companies are engineering solutions to these problems.